StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Income tax effect of non-GAAP adjustments by Year

Income tax effect of non-GAAP adjustments ($M) ($M)

Gilead Sciences Income tax effect of non-GAAP adjustments: -$647M in FY2025, down 58.9% from a year earlier.

Latest, FY2025
-647
Period ended Dec 31, 2025
Change on a year earlier
-58.9%
-1,574 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Income tax effect of non-GAAP adjustments above | (252) | (152) | (647) | (1,574)”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Gilead Sciences Income tax effect of non-GAAP adjustments ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-tax

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.